Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2

Manuela Di Fusco, Mary M Moran, Alejandro Cane, Daniel Curcio, Farid Khan, Deepa Malhotra, Andy Surinach, Amanda Miles, David Swerdlow, John M McLaughlin, Jennifer L Nguyen
doi: https://doi.org/10.1101/2021.10.12.21264707

Article usage

Article usage: October 2021 to October 2024

AbstractFullPdf
Oct 2021246951490
Nov 202171930248
Dec 202136828274
Jan 20221471445
Feb 2022111223
Mar 2022152824
Apr 202269214
May 202278325
Jun 202291120
Jul 202272410
Aug 20225119
Sep 2022721316
Oct 202261212
Nov 20223508
Dec 202241410
Jan 202344213
Feb 202356513
Mar 202339213
Apr 202343515
May 20233328
Jun 20233061
Jul 20233127
Aug 202343127
Sep 202344514
Oct 20233438
Nov 202339116
Dec 20232158
Jan 20241626
Feb 20242447
Mar 20242134
Apr 202413312
May 20241737
Jun 20242578
Jul 202419411
Aug 20241838
Sep 202421311
Oct 20242154
Back to top
Posted October 16, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2
Manuela Di Fusco, Mary M Moran, Alejandro Cane, Daniel Curcio, Farid Khan, Deepa Malhotra, Andy Surinach, Amanda Miles, David Swerdlow, John M McLaughlin, Jennifer L Nguyen
medRxiv 2021.10.12.21264707; doi: https://doi.org/10.1101/2021.10.12.21264707
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area